We expect decent Q4 results, with Germany nearing breakeven.
Better organic growth, less impressive margins '23e-'24e EBIT cut 3% Trading at 34x '23e EV/EBITDA v...
Additional delays in the finalisation of Ovzon-3 New launch slot is Jul-Sep'23 (previously Dec'22-Fe...
Q4'22 on Wednesday, 15 February Weaker consumer sentiment should impact sales of Organotex We expect...
Product mix and price hikes lift gross margin to 44.
Redeye comments on Better Collective’s preliminary Q4-results which was released this morning and ca...
Redeye updates its estimates and valuation following Mentice’s Q4 2022 report.
Redeye argues that the H2 report from Zwipe was largely in line with our expectations.
Redeye is positive to the commercial follow-up order of SEK4.
ChargePanel AB (publ) meddelade den 3 februari att bolaget har ingått ett tekniskt samarbete med Eas...
Gullberg & Jansson (”Gullberg” eller ”Bolaget”) producerar, marknadsför och distribuerar miljövänlig...
Redeye endorses CLS’ partnership with the Dutch company Soteria Medical.
Fortsatt påverkade av kostnadsinflation... Nettoomsättningen ökade 1,5% y/y till 1027 mkr (1012), me...
Q4 rapport Hansas rapport för det fjärde kvartalet var i stora drag i linje med våra förväntningar.
Redeye comments on Kontigo Cares Q4'22 report, in which Net Sales (SEK7.
Consti's net sales in Q4 amounted to EUR 93.3m, above our and consensus estimates (EUR 85.
Redeye provides its initial take on Mentice’s Q4 2022 report, which came in broadly below our estima...
Suominen’s Q4 comparable EBITDA of EUR 5m remained unchanged from previous quarter and missed consen...
Redeye sees a solid Q4 report from Addnode with strong organic and acquired growth.
Redeye argues that the second half-year report from Zwipe was largely in line with our expectations.
